You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Sanofi and Sobi present effective bleeding treatment

Sanofi and Swedish Orphan Biovitrum AB (Sobi) have presented positive results from the XTEND-1 pivotal phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa – also known as BIVV001.